UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB/A (X) Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the annual period ended JUNE 30, 2002 ( ) Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _____________ TO ______________ For the fiscal year ended June 30, 2002 Commission file number 0-21271 SANGUI BIOTECH INTERNATIONAL, INC. (Exact name of small business issuer as specified in its charter) Colorado 84-1330732 (State or other jurisdiction of (IRS Employer Identification Number) incorporation or organization) 1508 Brookhollow Drive, Suite 354 92705 ----- Santa Ana, CA 92705 (Zip Code) (Address of principal executive offices) Issuer's telephone number, including area code (714) 429-7807 Securities registered under Section 12(g) of the Exchange Act: Common Stock, no par value -------------------------- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-KSB/A to be signed on its behalf by the undersigned hereunto duly authorized. SANGUI BIOTECH INTERNATIONAL, INC. Date: October 17, 2002 /s/ Wolfgang Barnikol ----------------------------------- Wolfgang Barnikol President and Director PART I ------ ITEM 4. Submission of matters to a vote of security holders No matter was submitted to a vote of the Company's security holders during the fourth quarter covered by this Report. The Company encourages its shareholders to put forward shareholder proposals to be submitted to a vote of security holders in the course of a shareholders' meeting to be held in the first half of calendar year 2003. Shareholder proposals should arrive at the company's offices in Santa Ana, California, or Witten, Germany, no later than November 11, 2002. Shareholder proposals arriving later than this date will be adjourned to be submitted to a subsequent shareholders' meeting. CERTIFICATION PURSUANT TO 18 U.S.C.SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Sangui BioTech International, Inc. (the "Company") on Form 10-KSB/A the period ended June 30,2002, as filed with the Securities and Exchange Commission on the date hereof (the "Report"),the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: October 17, 2002 /s/ Wolfgang Barnikol --------------------------- Wolfgang Barnikol President and Director CERTIFICATION The undersigned, Prof. Dr. Dr. W. Barnikol, Chief Executive Officer and Chief Financial Officer, certifies that: 1. I have reviewed this annual report on Form 10-KSB/A of Sangui Biotech International, Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this annual report; and 3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report. Date: October 17, 2002 By: /s/ W. Barnikol --------------------------- Prof. Dr. Dr. W. Barnikol, Chief Executive Officer and Chief Financial Officer